Drug Trial Radar · NCT05212896
An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 26, 2021
Primary completion
Dec 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Dragonboat Biopharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- West China Hospital
- First posted
- Jan 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in human, open-label, exploratory phase I clinical study including dose escalation (Ia) and dose expansion (Ib) stage. It aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BC006 in giant cell tumor of tendon sheath (GCTTS) and other advanced solid tumors.
Conditions
- Advanced Solid Tumors (Including GCTTS)
Interventions
BC006Drug
BC006 monoclonal antibody injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: Up to 28 days
- Maximum Tolerated Dose (MTD) of BC006Time frame: Up to 28 days
- Recommended Dose for Expansion (RDE) of BC006Time frame: Through study completion, an average of 1 year
- Number of Participants with TEAEsTime frame: Through study completion, an average of 1 year
- Number of Participants with SAEsTime frame: Through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dragonboat Biopharmaceutical,Co.,Ltd
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.